

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hamed Aissaoui et al.

Application No.: 10/555,061

Confirmation No.: 9192

371(c) Date: October 28, 2005

Art Unit: 1624

For: QUINOXALINONE-3-ONE DERIVATIVES
AS OREXIN RECEPTOR ANTAGONISTS

Examiner: J.H. Murray

COMMUNICATION IN RESPONSE TO APRIL 9, 2008
NON-FINAL OFFICE ACTION (RESTRICTION REQUIREMENT)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Communication is submitted in response to an April 9, 2008 Non-Final Office Action (Restriction Requirement) issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A response to the April 9, 2008 Non-Final Office Action is due May 9, 2008. Accordingly, this Communication is being timely filed.

REMARKS

In the Office Action Summary for the outstanding April 9, 2008 Non-Final Office Action, the Examiner states that claims 1-14 are pending and are subject to restriction and/or election requirement in connection with the subject application. Applicants respectfully note that claims 6, 7 and 10 were canceled in a First Preliminary Amendment filed on October 27, 2005 with the U.S. Patent and Trademark Office concerning the